• Welcome to the Bio Law Blog. Our blog shares insights into intellectual property law for biologic medicines and related regulatory and legislative developments. We started this blog to engage in a conversation about the rapidly developing U.S. biosimilars pathway (the Biologics Price Competition and Innovation Act) and the recent surge in approvals for cutting-edge biologic products, such as siRNAs and cell-based and gene therapies. These new biologic products are changing medicine and posing new intellectual property questions and challenges. We also analyze developments in written description and enablement law for antibodies, the impact of Section 101 on biotech discoveries, and the increasing role of the Patent Trial and Appeal Board in reviewing biotech patents. We share a perspective as trial lawyers immersed in biology and biotech patent law.

    We are excited to be part of these transformative times for biologic medicines and to discuss them with you. We hope you enjoy our blog, and we welcome any questions, comments or suggestions.

    Subscribe for updates here.

    Featured Posts

    • Bio Law Blog
      Nov. 23, 2021
      Northern District of California Dismisses Challenge to PTAB’s Fintiv Factors
    • Bio Law Blog
      Nov. 16, 2021
      ChromaDex Milk Vitamin Formulation Patents Soured by Section 101
    Show Filters

    Recent Posts

    • Bio Law Blog
      Nov. 23, 2021
      Northern District of California Dismisses Challenge to PTAB’s Fintiv Factors
    • Bio Law Blog
      Nov. 16, 2021
      ChromaDex Milk Vitamin Formulation Patents Soured by Section 101
    • Bio Law Blog
      Nov. 09, 2021
      United States Calls for Supreme Court to Deny Petition for Certiorari Challenging Fintiv Factors
    • Bio Law Blog
      Sept. 22, 2021
      Northern District of Illinois Holds That a Biosimilar Applicant Is Not a Necessary Party to a BPCIA Lawsuit
    • Bio Law Blog
      Aug. 27, 2021

      Federal Circuit Invalidates Early
      CAR-T Patent

       

    • Bio Law Blog
      July 30, 2021
      Interchangeable Biosimilars Have Arrived in the U.S.

    Featured Perspectives

    • Articles
      July 28, 2021
      Life Sciences Patent Owners Face a Transformed Inter Partes Review Environment at the USPTO
    • Announcements
      July 28, 2021
      Hannah Lee Named to Daily Journal's 2021 Top 40 Under 40 List
    • Announcements
      July 28, 2021
      Lisa Kobialka Named to Managing IP's 2021 Top 250 Women in IP List
    • Announcements
      July 21, 2021
      Hannah Lee Named to Benchmark Litigation’s 2021 40 & Under Hot List
    • Announcements
      June 01, 2021
      Hannah Lee, Josh Winefsky Named Law360 Rising Stars
    • Announcements
      Aug. 13, 2020
      Irena Royzman Named to Benchmark’s 2020 Top 250 Women in Litigation
  • People

  • Perspectives